CHP
ACRS icon

Cable Hill Partners’s Aclaris Therapeutics ACRS Stock Holding History

Cable Hill Partners’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-279
Closed -$7K – 927
2017
Q3 		$7K Sell
279
-16
-5% -$429 ﹤0.01% 659
2017
Q2 		$8K Buy
+295
New +$8.02K ﹤0.01% 443

Other funds holding ACRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Cable Hill Partners's ACRS Position: Q4 2017 in Review

Cable Hill Partners sold out of Aclaris Therapeutics (ACRS) in Q4 2017, closing a stake of 279 shares — an estimated $7K sold.

Cable Hill Partners first reported a position in ACRS in Q2 2017 and held it in 2 quarters. The position peaked at $8K in Q2 2017. 102 funds tracked by Wall St. Rank hold ACRS as of Q4 2017.

  • Cable Hill Partners reported no remaining Aclaris Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Cable Hill Partners sold 279 Aclaris Therapeutics shares in Q4 2017, an estimated $7K.
  • Cable Hill Partners first reported a position in Aclaris Therapeutics in Q2 2017 and held it in 2 quarters.
  • Cable Hill Partners's Aclaris Therapeutics position peaked at $8K in Q2 2017.
  • 102 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2017.

Based on Cable Hill Partners's 13F filing for Q4 2017, filed 22 Feb 2018.